40047-23-2

Usage

Uses

Used in Pharmaceutical Industry:
6-Hydroxyindole-2-carboxylic acid is used as a chemical intermediate for the synthesis of indole-containing natural products, which are essential in the development of novel pharmaceutical compounds with potential therapeutic applications.
Used in Cancer Research and Treatment:
6-Hydroxyindole-2-carboxylic acid is utilized as a precursor in the development of drugs targeting cancer, given its potential to contribute to the creation of compounds with anticancer properties.
Used in Antioxidant and Anti-Inflammatory Drug Development:
6-Hydroxyindole-2-carboxylic acid is employed as a potential antioxidant and anti-inflammatory agent, indicating its use in the formulation of therapeutic drugs aimed at treating various ailments related to oxidative stress and inflammation.

InChI:InChI=1/C9H7NO3/c11-6-2-1-5-3-8(9(12)13)10-7(5)4-6/h1-4,10-11H,(H,12,13)

Upstream product

• 98081-83-5 methyl 6-methoxy-1H-indole-2-carboxylate 
• 24239-67-6 4-(benzyloxy)-1-methyl-2-nitrobenzene 
• 40047-21-0 (4-benzyloxy-2-nitro-phenyl)-pyruvic acid 
• 16732-73-3 6-Methoxyindole-2-carboxylic acid 
• 40047-22-1 6-(benzyloxy)-1H-indole-2-carboxylic acid 

Downstream Products

• 420135-92-8 RG 13579 
• 116350-38-0 6-hydroxy-1H-indole-2-carboxylic acid methyl ester 
• 890434-93-2 methyl 3-(4-aminophenyl)-6-(2-methoxyethoxy)-1H-indole-2-carboxylate 
• 890434-98-7 methyl 3-(4-aminophenyl)-6-(2-pyrrolidin-1-ylethoxy)-1H-indole-2-carboxylate 
• 1427753-33-0 benzyl 6-hydroxy-1H-indole-2-carboxylate 
• 1093256-05-3 3-bromo-N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-6-[(2-hydroxyethyl)oxy]-1H-indole-2-carboxamide 
• 1093631-46-9 6-[4-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-1H-indole-2-carboxylic acid 
• 1093631-72-1 1-(1,1-dimethylethyl) 2-methyl 6-(4-hydroxyphenyl)-1H-indole-1,2-dicarboxylate 

Relevant academic research and scientific papers

ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES

The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications

Replacement of the Benzylpiperidine Moiety with Fluorinated Phenylalkyl Side Chains for the Development of GluN2B Receptor Ligands

The 4-benzylpiperidine moiety is a central structural element of potent N-methyl-d-aspartate (NMDA) receptor antagonists containing the GluN2B subunit. To obtain novel GluN2B ligands suitable for positron emission tomography, the benzylpiperidine moiety was replaced with fluorinated ω-phenylalkylamino groups. For this purpose three primary propyl- and butylamines 7 a–c and one butyraldehyde 7 d bearing a fluorine atom and an ω-phenyl moiety were prepared in 3- to 7-step syntheses. Compounds 7 a–d were attached to various scaffolds of potent GluN2B antagonists (scaffold hopping) instead of the original 4-benzylpiperidine moiety. Although benzoxazol-2-ones and indoles with a benzylpiperidine moiety show high GluN2B affinity, the corresponding fluorophenylalkylamine derivatives did not result in high Glu2B affinity. Moderate GluN2B affinity was observed for a 3-(fluoroalkyl)-substituted tetrahydro-1H-3-benzazepine (Ki=239 nm). However, high GluN2B affinity was obtained for the tetrahydro-5H-benzo[7]annulen-7-amines 12 a–c (Ki=17–30 nm). Docking studies resulted in the same binding pose for 12 a as for the lead compound Ro 25-6981. It can be concluded that some GluN2B ligands (benzoxazolones, indoles) do not tolerate replacement of the 4-benzylpiperidine moiety with flexible fluorinated phenylalkyl side chains, but other scaffolds such as tetrahydro-3-benzazepines and -benzo[7]annulenes retain interaction with NMDA receptors containing the GluN2B subunit.

Demethylation of aromatic methyl ethers using ionic liquids under microwave irradiation

An efficient demethylation reaction for aromatic methyl ethers has been developed. Deprotection reactions give high yields with butylpyridinium bromide under microwave irradiation. Basic and acidic functional groups are tolerated if the reaction is performed under acidic conditions.

FARNESOID X RECEPTOR AGONISTS

The present invention relates to famesoid X receptors (FXR, NR1 H4) FXR is a member of the nuclear receptor class of ligand-activated transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceu

Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use

Compounds of formula (I): wherein R1, R5, R6, R7, Ar, L, A, and Q are as defined in the description, and to salts thereof, to compositions containing them, to the process for preparing them, and to their use as medicinal products, in particular as antican

Indole nitriles

Compounds of the formula (I) wherein m, n, R1, R2, R3, R4, R5 and R6 are as described herein, together with methods for making the compounds and using the compounds for treatment of diseases or conditions mediated by Cathepsin K.

Indole nitriles

Compounds of the formula (I) wherein m, n, R1, R2, R3, R4, R5and R6are as described herein, together with methods for making the compounds and using the compounds for treatment of diseases or conditions mediated by Cathepsin K.

Heteroaryl nitriles

The present invention relates to compound of formula (I) wherein R1, R2, R3, R4, R5 and n are as defined in the description and claims and pharmaceutically acceptable salts and/or pharmaceutically acc

Product based on inorganic or organic lamellar particles, containing a melanotic pigment, process for preparing it and its use in cosmetics

The invention relates to a product in powder form consisting of organic or inorganic particles having a lamellar structure, having a size of less than 50 microns and containing at least one synthetic melanotic pigment formed in situ by oxidation of an indole compound, and to its use for the protection of the human epidermis, in make-up products and for dyeing hair.

Process for dyeing keratin fibres with a monohydroxyindole associated with an iodide and hydrogen peroxide

Process for dyeing keratin fibres consisting in applying on these fibres a composition (A) containing at least one indole colorant of formula: STR1 where R1 =H or C1 -C4 alkyl; R2 and R3, which may be identical or different, denote H, C1 -C4 alkyl, carboxyl or alkoxycarbonyl; or a salt or a precursor of a compound (I), associated, either with iodide ions, or with H2 O2 ; application of composition (A) being preceded or followed by the application of a compound (B) which contains, either H2 O2 at a pH of 2 to 12 when (A) contains iodide ions, or iodide ions at a pH of 2 to 11 when (A) contains H2 O2. This process allows particularly powerful and resistant dyes to be made.